Insulin detemir in a twice daily insulin regimen versus a three times daily insulin regimen in the treatment of type 1 diabetes in children: A pilot randomized controlled trial

International Journal of Pediatric Endocrinology

Danièle Pacaud²  Alberto Nettel-Aguirre¹  Carol Huang²  Josephine Ho² 

[1] Department of Community Health Sciences, University of Calgary, Calgary, T3B 6A8 Canada;Department of Pediatrics, University of Calgary, Calgary, T3B 6A8, Canada

关键词: long acting insulin analogue;    pediatric;    glycemic control;    type 1 diabetes;   

Others  :  813624
DOI  :  10.1186/1687-9856-2011-15

 received in 2011-08-05, accepted in 2011-11-08,  发布年份 2011

【 摘 要 】

Background

Children with type 1 diabetes (DM1) often use three daily (TID) injections with intermediate acting insulin at breakfast and bedtime, and rapid acting insulin at breakfast and dinner. Substituting the evening intermediate acting insulin with a long acting insulin analogue (LAIA) at dinner in a twice daily (BID) injection regimen may be as effective as a TID regimen. The objective of this pilot study was to compare HbA1c in children with DM1 using a BID regimen with a LAIA at dinner (intervention) to those using a standard TID regimen (control) over 6 months.

Methods

Randomized controlled trial with main outcome measure being HbA1c at 0, 3 and 6 months. Secondary outcomes were frequency of adverse events (hypoglycemia, diabetic ketoacidosis, weight gain) and scores on the Diabetes Quality of Life Measure for Youth (DQOLY).

Results

18 subjects (10 control, 8 intervention). Mean years (standard deviations) for control and intervention respectively were: age at diagnosis of DM1 6.31 (2.91) vs 7.76 (3.22), duration of DM1 5.96 (4.95) vs 3.76 (3.37). No significant differences were seen in the mean HbA1c between control and intervention at 0 months [8.48(0.86) vs 8.57(1.13)], 3 months [8.47(0.50) vs 7.99(0.61)], or 6 months [8.42(0.63) vs 8.30(0.76)]. No significant differences were found between groups for frequency of adverse events or DQOLY.

Conclusions

In this pilot study, incorporating LAIA in a BID regimen did not cause deterioration in HbA1c or increases in adverse events; suggesting that this may be a viable option for families where a more simplified insulin regimen would be beneficial and compliance may be improved.

Trial registration

ClinicalTrials.gov: NCT00522210

【 授权许可】

   
2011 Ho et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM 1993, 329(14):977-986.
• [2]The Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Ped 1994, 125(2):177-188.
• [3]Skinner TC, Cameron FJ: Improving glycaemic control in children and adolescents: which aspects of therapy really matter? Diabet Med 27(4):369-375.
• [4]Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E: Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003, 26(3):590-596.
• [5]Plank J, Bodenlenz M, Sinner F, Magnes C, Gorzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR: A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005, 28(5):1107-1112.
• [6]Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004, 27(5):1081-1087.
• [7]Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004, 53(6):1614-1620.
• [8]Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA: Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003, 26(11):3087-3092.
• [9]Ingersoll GM, Marrero DG: A modified quality-of-life measure for youths: psychometric properties. The Diabetes Educator 1991, 17(2):114-118.
• [10]Hirsch IB: Insulin analogues. NEJM 2005, 352(2):174-183.
• [11]Haffner MC, Kufner MP: Insulin analogues. NEJM 2005, 352(17):1822-1824.
• [12]Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T: Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Diabet Med 2006, 23(5):522-528.
• [13]Cengiz E, Sherr JL, Erkin-Cakmak A, Weinzimer SA, Burke EN, Sikes KA, Urban AD, Tamborlane WV: A Bridge to Insulin Pump Therapy: Bid Regimen with NPH and Detemir Insulin During Initial Treatment of Youth with Type 1 Diabetes (T1D). Endocr Pract 2011, 1-17.
• [14]Dundar BN, Dundar N, Eren E: Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy. J Clin Res Ped Endo 2009, 1(4):181-187.
• [15]Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J: Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007, 24(1):27-34.
• [16]Braun D, Konrad D, Lang-Muritano M, Schoenle E: Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes. Pediatric Diabetes 2008, 9(4 Pt 2):382-387.
• [17]Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S: Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study. Pediatric Diabetes 2009, 10(6):401-407.
• [18]Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M: Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001, 24(2):296-301.
• [19]Karges B, Kapellen T, Neu A, Hofer SE, Rohrer T, Rosenbauer J, Wolf J, Holl RW: Long-acting insulin analogs and the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes: a prospective study of 10, 682 patients from 271 institutions. Diabetes Care 2010, 33(5):1031-1033.
• [20]Nguyen TM, Renukuntla VS, Heptulla RA: Mixing insulin aspart with detemir does not affect glucose excursion in children with type 1 diabetes. Diabetes Care 2010, 33(8):1750-1752.